Ruxolitinib ni molekile ntoya ya Janus kinase inhibitor ikoreshwa mukuvura myelofibrosis yo hagati cyangwa ibyago byinshi ndetse nuburyo bwihanganira polycythemia vera hamwe nindwara ya graft-vs.Ruxolitinib ifitanye isano nigihe gito kandi mubisanzwe byoroheje muri serumu aminotransferase mugihe cyo kuvura ndetse no mubihe bidasanzwe byo kwikomeretsa, kugaragara kwa clinique idiosyncratic bikomeretsa umwijima kimwe no kwandura hepatite B kubantu bakunze kwibasirwa.

Ruxolitinib ni bioavailable ya Janus ifitanye isano na kinase (JAK) inhibitor hamwe nibikorwa bya antineoplastique na immunomodulation.Ruxolitinib ihuza cyane kandi ikabuza poroteyinetyrosinekinase JAK 1 na 2, zishobora gutuma kugabanuka k'umuriro no kubuza ikwirakwizwa rya selile.Inzira ya JAK-STAT (transducer ya signal na activate ya transcription) inzira igira uruhare runini mukumenyekanisha cytokine nyinshi nibintu bikura kandi ikagira uruhare mukwirakwiza selile, gukura, hematopoiesis, hamwe no gukingira indwara;JAK kinase irashobora gutegekwa muburwayi butwika, myeloproliferative disorders, na malignancies zitandukanye.

Ruxolitinib ni apyrazoleyasimbuwe kumwanya wa 1 nitsinda rya 2-cyano-1-cyclopentylethyl naho kumwanya wa 3 nitsinda rya pyrrolo [2,3-d] pyrimidin-4-yl.Ikoreshwa nkumunyu wa fosifate mukuvura abarwayi bafite myelofibrosis hagati cyangwa ibyago byinshi, harimo myelofibrosis primaire, post-polycythemia vera myelofibrosis na trombocythemia myelofibrosis.Ifite uruhare nka antineoplastique na EC 2.7.10.2 (proteine ​​idasanzwe-tyrosinekinase) inhibitor.Ni nitrile, apyrrolopyrimidinen'umunyamuryango wa pyrazoles.